Previous 10 | Next 10 |
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Amarin Corporation PLC ( AMRN ) is currently on a roll as the company is gearing up for the expanded market launch of its potential blockbuster drug Vascepa, which is now the only drug approved in the United States for lowering the risk of cardiovascular events in conjunction with statin the...
The following slide deck was published by Amarin Corporation plc in conjunction with this Read more ...
Amarin Corporation PLC (AMRN) 38th Annual J.P Morgan Healthcare Conference January 15, 2020, 13:30 ET Company Participants John Thero - President, CEO & Director Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Presentation Jessica Fye Hey, good...
A flurry of events have hit the omega-3 landscape on January 13. Long story short, it looks like Amarin ( AMRN ) will be able to rapidly dominate the prescription omega-3 market over the course of 2020 and for the foreseeable future. Quick intro to omega-3s As a quick reminder, the main ma...
A company with research centered around each of these divisions, like a cluster of trees each growing additional branches form its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in several new industries ...
AstraZeneca (NYSE: AZN) announced on Monday that it was discontinuing the phase 3 Strength clinical study evaluating Epanova in reducing cardiovascular risk. The British drugmaker said that the decision was made after the study's independent data monitoring committee determined that there ...
Acasti Pharma (NASDAQ: ACST ) craters 60% premarket on modest volume (thus far) in response to unsuccessful results from a Phase 3 clinical trial, TRILOGY 1 , evaluating lead candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia. More news o...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the launch of True To Your Heart , an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent c...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Wat...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...